Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

A method of treating cancer according to a 28-day cycle of intermittent paclitaxel and relacorilant administration, wherein said 28-day cycle begins on day0, wherein said cancer comprises a solid tumor, comprising the following administrations to a patient in need of treatment for said cancer:

• a) administering an effective oral dose of relacorilant of between about 75 milligrams (mg) to about 200 mg on day 0, day 7, and day 14 of said 28-day cycle of intermittent paclitaxel and relacorilant administration;
• and then, b) administering, on day 1, day 8, and day 15 of said 28-day cycle of intermittent paclitaxel and relacorilant administration, an effective oral dose of relacorilant of between about 75 mg to about 200 mg and an effective dose of paclitaxel that is reduced by about 20% to about 35% from the paclitaxel single agent dose of about 100 mg/m2 to about 125 mg/m2, wherein said single agent dose is the paclitaxel dose to be administered when paclitaxel is administered without other pharmaceutical agents;
• and then, c) administering, on day 2, day 9 and day 16 of said 28-day cycle of intermittent paclitaxel and relacorilant administration an effective oral dose of relacorilant of between about 75 mg to about 200 mg, wherein steps a), and b), and c) are intermittent administration steps in which paclitaxel administration is performed on days 1, 8, and 15 of said 28-day cycle, and in which relacorilant administration is performed on the day before, the day of, and the day after said paclitaxel administration, effective to provide the patient with an effective level of relacorilant and an effective level of paclitaxel at the same time, whereby the cancer comprising a solid tumor is treated according to a 28-day cycle of intermittent paclitaxel and relacorilant administration.